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and the organic solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography using EtOAc-DCM (1:4, v/v) to afford compound 9a as a pink solid (0.61 g, 52%). mp: 101.6 °C (decomposed). 1 
2-(Bromomethyl)-4-methoxyquinoline (9b)
Following procedure A, starting with 8b, compound 9b was obtained as a pink solid (0.59 g, 50%). 
2-(Bromomethyl)-4-methoxyquinoline (9c)
Following procedure A, starting with 5-methoxy-2-methylquinoline, compound 9c was obtained as a pink solid (0.62 g, 53%). 
S7
Following procedure A, starting with 7-methoxy-2-methylquinoline, compound 9e was obtained as a pink solid (0.71 g, 60% 
4-Methoxy-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy) methyl)quinolone (10b)

S9
8-Methoxy-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinolone (10f)
Following procedure B, starting with compounds 6 and 9f, compound 10f was obtained as a white solid (0.25 g, 59%). 1 S11 mL) were added. The reaction mixture was continually stirred overnight. 
1-(4-
Bromophenyl
4-(3-(4-Bromophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine (15)
Compound 14 (1.82 g, 6.6 mmol) was added into N-dimethoxymethyl-N,N-dimethylamine (16 mL) and the reaction mixture was refluxed for 1 h. Excess N-dimethoxymethyl-N,N-dimethylamine was removed under vacuum. The residue was dissolved in EtOH (20 mL). After methylhydrazine (0.31 g, 6.6 mmol) and concentrated sulfuric acid (0.1 mL) were added into the above solution, the reaction mixture was stirred for 1 h at room temperature. After removing the solvent by S17 was purified via silica gel chromatography using MeOH-DCM (1:10, v/v) to afford compound 10k (37 mg, 47%) as a yellow solid. 1 C, H, N.
N-((6-methoxyquinolin-2-yl)methyl)-4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)aniline (10l)
Following procedure D, starting with compounds 20 and 9d, compound 10l was obtained (39 mg, 49%) as a yellow solid. 
N-((7-methoxyquinolin-2-yl)methyl)-4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)aniline (10m)
Following procedure D, starting with compounds 20 and 9e, compound 10m was obtained (33 mg, 43%) as a yellow solid. 
N-((8-methoxyquinolin-2-yl)methyl)-4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)aniline (10n)
Following procedure D, starting with compounds 20 and 9f, compound 10n was obtained (31 mg, 40%) as a yellow solid. S19 
In Vitro Assay
The PDE10A in vitro binding assay followed published procedures. 1-5 PDE activity was measured using the Phosphodiesterase 
S20
independently assayed for at least two times and the fitting R squares were at least 90%. All results were described as fitted IC 50 ± standard derivations with unit of nM.
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